source
- Trump's MFN drug pricing agreements complicate new drug launchesPresident Donald Trump announced nine new agreements with drug manufacturers on Aug. 31, extending the “most favored nation” (MFN) pricing framework. Under MFN, U.S. prices for participating drugs…
- FDA requires GLP-1 drug labels to include warning about rare eye diseaseThe FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…